Biopharmaceutical company
3 AI-extracted insights from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Not enough scored insights about SELLAS Life Sciences Group, Inc. in the last 30 days yet.
The 1 sources with the most insights about SELLAS Life Sciences Group, Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Extremely bearish view with a strong recommendation to 'sell everything' and 'get the fuck out of it ASAP'. The speaker believes the company's drug 'does not work' and notes a 400% borrow rate, indicating high short interest.
The speaker calls the stock 'a short', but notes it is difficult to time because the data release for its 'biggest binary' event is 'very opaque'.
The speaker expressed a simple bullish sentiment, noting its recent favorable price action: 'SLS has been creeping up. I like it. Let's go.'
Extremely bearish view with a strong recommendation to 'sell everything' and 'get the fuck out of it ASAP'. The speaker believes the company's drug 'does not work' and notes a 400% borrow rate, indicating high short interest.
The speaker calls the stock 'a short', but notes it is difficult to time because the data release for its 'biggest binary' event is 'very opaque'.
The speaker expressed a simple bullish sentiment, noting its recent favorable price action: 'SLS has been creeping up. I like it. Let's go.'
Other assets that creators frequently mention in the same content as SELLAS Life Sciences Group, Inc..
The most active sources covering SELLAS Life Sciences Group, Inc. (SLS) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 3 AI-extracted insights about SELLAS Life Sciences Group, Inc. (SLS) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering SELLAS Life Sciences Group, Inc. (SLS) most frequently also discuss QBTS, IONQ, SRPT, NVDA, ARCT. See the "Discussed alongside" section above for full asset pages.